John Pagel, MD Swedish Cancer Institute discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia https://www.globenewswire.com/news-release/2020/08/06/2074302/0/en/Adaptive-Biotechnologies-Receives-Expanded-FDA-Clearance-for-the-clonoSEQ-Assay-to-Assess-Minimal-Residual-Disease-MRD-in-Patients-with-Chronic-Lymphocytic-Leukemia.html
Author: Editor
Brian Koffman, MD CLL Society Inc. discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess MRD in Patients with Chronic Lymphocytic Leukemia https://www.globenewswire.com/news-release/2020/08/06/2074302/0/en/Adaptive-Biotechnologies-Receives-Expanded-FDA-Clearance-for-the-clonoSEQ-Assay-to-Assess-Minimal-Residual-Disease-MRD-in-Patients-with-Chronic-Lymphocytic-Leukemia.html
Brian Koffman, MD CLL Society Inc. discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess MRD in Patients with Chronic Lymphocytic Leukemia https://www.globenewswire.com/news-release/2020/08/06/2074302/0/en/Adaptive-Biotechnologies-Receives-Expanded-FDA-Clearance-for-the-clonoSEQ-Assay-to-Assess-Minimal-Residual-Disease-MRD-in-Patients-with-Chronic-Lymphocytic-Leukemia.html
Brian Koffman, MD CLL Society Inc. discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess MRD in Patients with Chronic Lymphocytic Leukemia https://www.globenewswire.com/news-release/2020/08/06/2074302/0/en/Adaptive-Biotechnologies-Receives-Expanded-FDA-Clearance-for-the-clonoSEQ-Assay-to-Assess-Minimal-Residual-Disease-MRD-in-Patients-with-Chronic-Lymphocytic-Leukemia.html
Mark Stroh, Ph.D. – CytomX Therapeutics discusses CX-2009 Abstract – a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer and CX-072 Abstract – Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab. ASCO2020 CX-2009 https://meetinglibrary.asco.org/record/188112/abstractPROCLAIM- CX072 https://meetinglibrary.asco.org/record/186711/abstract Â
Mark Stroh, Ph.D. – CytomX Therapeutics discusses CX-2009 Abstract – a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer and CX-072 Abstract – Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab. ASCO2020 CX-2009 https://meetinglibrary.asco.org/record/188112/abstractPROCLAIM- CX072 https://meetinglibrary.asco.org/record/186711/abstract Â
Mark Stroh, Ph.D. – CytomX Therapeutics discusses CX-2009 Abstract – a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer and CX-072 Abstract – Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab. ASCO2020 CX-2009 https://meetinglibrary.asco.org/record/188112/abstractPROCLAIM- CX072 https://meetinglibrary.asco.org/record/186711/abstract Â
Timothy Heuer, Ph.D., twoXAR Pharmaceuticals discusses Presents Positive Preclinical Safety & Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 AACR2020 https://www.prnewswire.com/news-releases/twoxar-pharmaceuticals-presents-positive-preclinical-safety-and-efficacy-data-for-its-novel-investigational-cancer-treatment-txr-311-301080554.html
Timothy Heuer, Ph.D., twoXAR Pharmaceuticals discusses Presents Positive Preclinical Safety & Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 AACR2020 https://www.prnewswire.com/news-releases/twoxar-pharmaceuticals-presents-positive-preclinical-safety-and-efficacy-data-for-its-novel-investigational-cancer-treatment-txr-311-301080554.html
Marco Timmers, Ph.D., CEO – Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate multiple novel ADCs https://www.biospace.com/article/byondis-initiates-phase-ii-study-of-antibody-drug-conjugate-vic-trastuzumab-duocarmazine-in-advanced-endometrial-cancer-/
Marco Timmers, Ph.D., CEO – Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate multiple novel ADCs https://www.biospace.com/article/byondis-initiates-phase-ii-study-of-antibody-drug-conjugate-vic-trastuzumab-duocarmazine-in-advanced-endometrial-cancer-/
Marco Timmers, Ph.D., CEO – Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate multiple novel ADCs https://www.biospace.com/article/byondis-initiates-phase-ii-study-of-antibody-drug-conjugate-vic-trastuzumab-duocarmazine-in-advanced-endometrial-cancer-/
Marco Timmers, Ph.D., CEO – Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate multiple novel ADCs https://www.biospace.com/article/byondis-initiates-phase-ii-study-of-antibody-drug-conjugate-vic-trastuzumab-duocarmazine-in-advanced-endometrial-cancer-/
Jeffrey A. Meyerhardt, MD, MPH, FASCO – Dana-Farber Cancer Institute discusses Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702
Jeffrey A. Meyerhardt, MD, MPH, FASCO – Dana-Farber Cancer Institute discusses Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702
Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care – Mallinckrodt discusses Mallinckrodt and Terumo BCT Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Treatment of Cutaneous T-Cell Lymphoma (CTCL) in Adults
Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care – Mallinckrodt discusses Mallinckrodt and Terumo BCT Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Treatment of Cutaneous T-Cell Lymphoma (CTCL) in Adults
Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care – Mallinckrodt discusses Mallinckrodt and Terumo BCT Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Treatment of Cutaneous T-Cell Lymphoma (CTCL) in Adults
In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Tim Blauwkamp, Ph.D., Chief Scientific Officer and co-founder of Karius.Karius, based in Redwood City, CA, has developed a non-invasive liquid biopsy, a blood test, called the Karius Test®. The test is based on next-generation sequencing of microbial cell-free DNA and can rapidly detect pathogens causing serious infections, including those diseases that are difficult to diagnose through conventional methods. The test can identify and quantify over 1,000 clinically relevant pathogens, including bacteria, DNA viruses, fungi, and parasites. The test can be used to identify infections related to complicated and…
In this edition of The Onco’Zine Brief, Peter Hofland, Ph.D., talks with Vince McRuiz and Margo Shoup, MD, FACS.Margo Shoup is a nationally recognized surgical oncologist who specializes in gastrointestinal cancers and sarcomas. She is also the senior vice president, and system chair of the Nuvance Health Cancer Institute, where she provides strategic and clinical leadership for all aspects of Nuvance Health’s cancer services.Vince McRuiz is a patient of Dr. Shoup.In March 2020 just as the COVID-19 pandemic was ramping up in the northeastern United States, Vince was diagnosed with a retroperitoneal sarcoma — a rare abdominal cancer —that develops…
In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Armon Sharei, Ph.D. Chief Executive Officer of SQZ Biotech, about the development and manufacturing of cell therapies. Traditionally, the foundation of cancer treatment included surgery, chemotherapy, and radiation therapy. But over the last few decades, targeted therapies —drugs that specifically, target molecular changes seen primarily on cancer cells—have become a standard treatment for many cancers. In addition, over the past several years, immunotherapies—therapies that are designed to use the power of a patient’s own immune system to attack cancer, have emerged as a new treatment. One of the…
In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Cristian Massacesi, MD, Senior Vice President, Head of Late Development Oncology R&D at AstraZeneca and with Jeffrey Skolnik, MD, Vice President, Clinical Development at Inovio Pharmaceuticals about new data and exciting developments both companies are presenting during the 2020 virtual annual meeting of the American Society of Clinical Oncology – ASCO.This year, amidst the SAR-CoV-2 or coronavirus pandemic, the ASCO organization has been hard at work to offer a unique scientific program for oncology professionals, patient advocates, and industry representatives.In the program, Hofland and Massacesi talk about AZD9833,…
In this edition of The Onco’Zine Brief, Peter Hofland talking with Helen Sabzevari, the president of Precigen. Precigen is a biopharmaceutical company dedicated to the discovery and clinical-stage development of the next generation of gene and cell therapies using precision technology. The company is developing novel therapeutic agents that are designed to target the most urgent and difficult diseases in immuno-oncology, autoimmune disorders, and infectious diseases.During the second part of the virtual meeting of the American Association of Clinical Research – AACR – being held June 22 to June 24, 2020, the company presented preclinical results of an investigational drug…
In this episode of The Onco’Zine Brief, Peter Hofland talks with Thorsten Sperber, Global Head Medical Affairs at Immunomedics. Hofland and Sperber talk about sacituzumab govitecan, a novel antibody-drug conjugate. At the time of the interview, the drug was not yet approved, but in the weeks following the interview, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan (Trodelvyâ„¢) for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease.Sacituzumab govitecan, previously known as IMMU-132, is Immunomedics’ lead product and the most…
In this episode of The Onco’Zine Brief, Peter Hofland talks with Terri Conneran, a lung cancer survivor and patient advocate. Struggling in the heat and humidity of the summer of 2016, Terri Conneran believed that her asthma was uncontrolled. In August that year, her physician assistant prescribed her a preventive inhaler. That autumn brought the excuse of allergies, plus time for the new inhaler to take effect. By Christmas 2016, nasal congestion, and a heavy feeling chest with shortness of breath it was time to again see her doctor. Hearing fluid in her lungs, an x-ray showed a mass with…
In this episode of The Onco’Zine Brief, recorded during the 42nd San Antonio Breast Cancer Symposium (SABCS) held December 10 – 14, 2019 in San Antonio, Texas, Peter Hofland talks with Susan Rafte, a 25+ year survivor of metastatic breast cancer and patient advocate.In 1994, eight and a half months after birth to her daughter Marika, Susan Rafte, only 30 years old, was diagnosed with stage III ductal carcinoma.While she was pregnant with her daughter, she first felt a lump in her breast. Her doctors attributed the lump to her pregnancies. However, 18 months later, when Rafte pushed for a…
In this edition of The Onco’Zine Brief, recorded during the 42nd San Antonio Breast Cancer Symposium (SABCS), held December 10 – 14, 2019 in San Antonio, Texas, Peter Hofland talks with leading breast cancer experts and patients about metastatic breast cancer and health-related quality of life hrQoL issues including sexual intimacy, bone health and joint pain. In this roundtable, panelists will also discuss liquid biomarkers for disease progression in the metastatic setting.The expert panel includes; David Portman, MD, founder and Chief Executive Officer (CEO) of Sermonix Pharmaceuticals. Portman is a respected Key Opinion Leader (KOL) in the field, presented clinical…
Neal Shore, MD, FACS – LUGPA discusses Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Olaparib for Metastatic Castration-Resistant Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Olaparib for Metastatic Castration-Resistant Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
In this edition of The Onco’Zine Brief Peter Hofland talks with Catherine Ivy, the Founder and President of the Ben & Catherine Ivy Foundation. The Ben & Catherine Ivy Foundation, established in 2005, is the largest non-government organization supporter of brain tumor – including glioblastoma (GBM) – research in the world. To date, the Ivy Foundation has funded clinical trials and basic science in North America, Europe, and Asia. Glioblastoma, also known as glioblastoma multiforme, is an aggressive type of cancer that can occur in the brain or spinal cord. Glioblastoma forms from cells called astrocytes, that support nerve cells. The…
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy
Dre Benedetta Guani – University Hospital of Lausanne discusses Histopathologic validation of the sentinel node technique in early-stage cervical cancerASCOhttps://meetinglibrary.asco.org/record/187420/abstract
Dre Benedetta Guani – University Hospital of Lausanne discusses Histopathologic validation of the sentinel node technique in early-stage cervical cancerASCOhttps://meetinglibrary.asco.org/record/187420/abstract
Liv Johannessen, P.h.D.Syros Pharmaceuticals discusses Activity of SY-5609 an oral noncovalent potent and selective CDK7 inhibitor in preclinical models of colorectal cancerhttps://meetinglibrary.asco.org/record/188034/abstractASCO2020
Liv Johannessen, P.h.D. Syros Pharmaceuticals discusses Activity of SY-5609 an oral noncovalent potent and selective CDK7 inhibitor in preclinical models of colorectal cancer https://meetinglibrary.asco.org/record/188034/abstract ASCO2020
Jeff Petty, MD Wake Forest Baptist Health discusses Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelcaâ„¢ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer
Jeff Petty, MD Wake Forest Baptist Health discusses Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelcaâ„¢ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer
Jeff Petty, MD Wake Forest Baptist Health discusses Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelcaâ„¢ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer
Siqing Fu, M.D., Ph.D. MD Anderson Cancer Center discusses Soricimed Announces Resumption of MD Anderson’s Investigator-Initiated Phase 1b Clinical Trial of SOR-C13 https://www.firstwordpharma.com/node/1731315
Siqing Fu, M.D., Ph.D. MD Anderson Cancer Center discusses Soricimed Announces Resumption of MD Anderson’s Investigator-Initiated Phase 1b Clinical Trial of SOR-C13  https://www.firstwordpharma.com/node/1731315
Robert Epstein, MD – Epstein Health, LLC. – discusses Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey of patients with cancer. https://meetinglibrary.asco.org/record/190476/abstract #ASCO2020
Robert Epstein, MD – Epstein Health, LLC. – discusses Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey of patients with cancer. https://meetinglibrary.asco.org/record/190476/abstract #ASCO2020
Robert Epstein, MD – Epstein Health, LLC. – discusses Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey of patients with cancer. https://meetinglibrary.asco.org/record/190476/abstract #ASCO2020